TopoTarget A/S Release: Final Data From BELIEF Study for American Society of Clinical Oncology 2013 Confirms Objective Response Rate of 26%

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Topotarget announces that an abstract containing positive final data from the registrational BELIEF study with belinostat in peripheral T-cell lymphoma (PTCL) has been released for presentation on ASCO (American Society of Clinical Oncology) 2013 on May 31-June 4, 2013. The abstract concludes that the BELIEF study has an objective response rate (ORR) of 26%.

Help employers find you! Check out all the jobs and post your resume.

Back to news